RNA is a premier journal in the field of molecular biology, published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. With an impressive impact factor reflected by its Q1 status in the Molecular Biology category, this journal has established itself as an essential resource for researchers and professionals dedicated to understanding the role of RNA in biological processes. Spanning over two decades of impactful research from 1995 to 2024, RNA covers a broad spectrum of topics, including RNA biology, gene regulation, and therapeutic innovations. Researchers can access its extensive array of original research articles, reviews, and commentary, making it a vital conduit for new discoveries and methodologies in the field. With its high ranking within Scopus at Rank #115/410 and a 72nd percentile ranking in the domain of Biochemistry, Genetics, and Molecular Biology, RNA continues to advance the understanding of RNA and its critical contributions to life sciences.

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

Frontiers in Genetics is a premier academic journal dedicated to advancing the field of genetics through high-quality, peer-reviewed research. Published by FRONTIERS MEDIA SA in Switzerland since 2010, this Open Access journal provides a platform for researchers and practitioners to disseminate innovative findings across various subfields, including clinical genetics and molecular medicine. With a notable emphasis on interdisciplinary approaches, the journal holds a strong position in the academic landscape, achieving Q2 rankings in key categories such as Genetics and Molecular Medicine in 2023. Not only does Frontiers in Genetics contribute to the scholarly dialogue by publishing impactful studies, but it also promotes accessibility to vital research, ensuring that knowledge is available to a global audience. This journal is a vital resource for researchers, professionals, and students looking to stay at the forefront of genetic discoveries and their applications, reflective of its engagement with contemporary challenges in genetics and healthcare.

Non-coding RNA Research, published by KEAI PUBLISHING LTD, is a leading open-access journal dedicated to advancing the field of non-coding RNA, a critical component in the landscape of molecular biology and genetics. Established in 2016, this journal aims to provide a platform for the dissemination of high-quality research focusing on the roles, mechanisms, and therapeutic potentials of non-coding RNAs in various biological processes and diseases. With impressive Scopus rankings placing it in the top quartile for both Biochemistry and Medical Biochemistry, as well as notable standings in Genetics and Molecular Biology, Non-coding RNA Research continues to attract contributions from globally recognized experts. The journal's commitment to open access ensures broad visibility and engagement with cutting-edge discoveries, thereby fostering an inclusive scientific dialogue that enhances understanding and innovation in this rapidly evolving field. For researchers and scholars, the opportunity to publish in a Q1 ranked journal not only validates their work but also enhances its impact, making Non-coding RNA Research an indispensable resource for anyone interested in the intricate workings of non-coding RNA.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

MOLECULAR MEDICINE, published by SPRINGER, is a leading scholarly journal dedicated to advancing the fields of genetics and molecular biology with a focus on clinical applications. Since its inception in 1994, it has evolved to become a pivotal platform for disseminating innovative research findings, achieving a remarkable Q1 ranking in multiple categories, including Genetics, Molecular Biology, and Molecular Medicine as of 2023. Featuring an Open Access model since 2000, the journal ensures that cutting-edge research is freely available to the global scientific community, facilitating collaboration and knowledge exchange. With a commitment to high-quality peer-reviewed content, MOLECULAR MEDICINE serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of molecular research and its implications for medical science. For those interested in contributing to or accessing vital research in this dynamic field, MOLECULAR MEDICINE stands out as a premier choice.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.